{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T07:14:06Z","timestamp":1770966846631,"version":"3.50.1"},"reference-count":24,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2022.13429","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T11:49:43Z","timestamp":1657712983000},"source":"Crossref","is-referenced-by-count":11,"title":["Thyroid dysfunction during PD\u20111 inhibitor treatment in patients with cancer: Incidence and association with progression\u2011free survival"],"prefix":"10.3892","volume":"24","author":[{"given":"Yanfei","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Pathology, Navy Medical Center of People Liberation Army, Naval Medical University, Shanghai 200433, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Radiation Injury Protection and Treatment, Navy Medical Center of People Liberation Army, Naval Medical University, Shanghai 200433, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxia","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Baotou Central Hospital, Baotou, Inner Mongolia Autonomous Region 014040, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Baotou Tumor Hospital, Baotou, Inner Mongolia Autonomous Region 014030, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2022,7,13]]},"reference":[{"key":"key20220826100500_b1-ol-24-03-13429","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1080\/21645515.2019.1571892","article-title":"PD-1 and PD-L1 in cancer immunotherapy: Clinical implications and future considerations","volume":"15","author":"Jiang","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"key20220826100500_b2-ol-24-03-13429","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-981-15-3266-5_3","article-title":"Roles of PD-1\/PD-L1 pathway: Signaling, cancer, and beyond","volume":"1248","author":"Ai","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"key20220826100500_b3-ol-24-03-13429","first-page":"727","article-title":"PD-1\/PD-L1 pathway: Current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am J Cancer Res"},{"key":"key20220826100500_b4-ol-24-03-13429","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1136\/jclinpath-2017-204853","article-title":"Pd-L1","volume":"71","author":"Kythreotou","year":"2018","journal-title":"J Clin Pathol"},{"key":"key20220826100500_b5-ol-24-03-13429","first-page":"174","article-title":"Landscape of PD-1\/PD-L1 regulation and targeted immunotherapy","volume":"33","author":"Ni","year":"2018","journal-title":"Chin Med Sci J"},{"key":"key20220826100500_b6-ol-24-03-13429","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/s41419-020-03140-2","article-title":"PD-L1 degradation pathway and immunotherapy for cancer","volume":"11","author":"Gou","year":"2020","journal-title":"Cell Death Dis"},{"key":"key20220826100500_b7-ol-24-03-13429","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and function of the PD-L1 checkpoint","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity"},{"key":"key20220826100500_b8-ol-24-03-13429","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s11899-020-00589-y","article-title":"PD-1\/PD-L1 pathway and its blockade in patients with classic hodgkin lymphoma and non-hodgkin large-cell lymphomas","volume":"15","author":"Xie","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"key":"key20220826100500_b9-ol-24-03-13429","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.csbj.2019.03.006","article-title":"Application of PD-1 blockade in cancer immunotherapy","volume":"17","author":"Wu","year":"2019","journal-title":"Comput Struct Biotechnol J"},{"key":"key20220826100500_b10-ol-24-03-13429","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.canlet.2017.08.006","article-title":"PD-1\/PD-L1 and immunotherapy for pancreatic cancer","volume":"407","author":"Feng","year":"2017","journal-title":"Cancer Lett"},{"key":"key20220826100500_b11-ol-24-03-13429","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1007\/s10147-019-01548-1","article-title":"Combination therapy with PD-1 or PD-L1 inhibitors for cancer","volume":"25","author":"Hayashi","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"key20220826100500_b12-ol-24-03-13429","doi-asserted-by":"publisher","first-page":"16824","DOI":"10.1002\/jcp.28358","article-title":"PD-1\/PD-L1 pathway: Basic biology and role in cancer immunotherapy","volume":"234","author":"Salmaninejad","year":"2019","journal-title":"J Cell Physiol"},{"key":"key20220826100500_b13-ol-24-03-13429","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.7150\/thno.50333","article-title":"From biomarkers to therapeutic targets: The promise of PD-L1 in thyroid autoimmunity and cancer","volume":"11","author":"D'Andrea","year":"2021","journal-title":"Theranostics"},{"key":"key20220826100500_b14-ol-24-03-13429","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.tcm.2019.02.011","article-title":"Subclinical thyroid dysfunction and cardiovascular consequences: An alarming wake-up call?","volume":"30","author":"Manolis","year":"2020","journal-title":"Trends Cardiovasc Med"},{"key":"key20220826100500_b15-ol-24-03-13429","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40618-017-0778-8","article-title":"Thyroid dysfunctions secondary to cancer immunotherapy","volume":"41","author":"Chalan","year":"2018","journal-title":"J Endocrinol Invest"},{"key":"key20220826100500_b16-ol-24-03-13429","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann Oncol"},{"key":"key20220826100500_b17-ol-24-03-13429","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1089\/thy.2019.0726","article-title":"Overt thyroid dysfunction and anti-thyroid antibodies predict response to anti-PD-1 immunotherapy in cancer patients","volume":"30","author":"Basak","year":"2020","journal-title":"Thyroid"},{"key":"key20220826100500_b18-ol-24-03-13429","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12902-017-0215-1","article-title":"Thyroid function and metabolic syndrome in the population-based LifeLines cohort study","volume":"17","author":"Wolffenbuttel","year":"2017","journal-title":"BMC Endocr Disord"},{"key":"key20220826100500_b19-ol-24-03-13429","first-page":"2140","article-title":"Clinical features of immune-related thyroid dysfunction and its association with outcomes in patients with advanced malignancies treated by PD-1 blockade","volume":"18","author":"Sakakida","year":"2019","journal-title":"Oncol Lett"},{"key":"key20220826100500_b20-ol-24-03-13429","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.anl.2014.12.002","article-title":"Thyroid dysfunction after intra-arterial chemotherapy for hypopharyngeal and laryngeal cancer","volume":"42","author":"Endo","year":"2015","journal-title":"Auris Nasus Larynx"},{"key":"key20220826100500_b21-ol-24-03-13429","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1080\/00365513.2020.1742369","article-title":"Immune checkpoint inhibitors of the PD-1\/PD-L1-axis in non-small cell lung cancer: Promise, controversies and ambiguities in the novel treatment paradigm","volume":"80","author":"Breimer","year":"2020","journal-title":"Scand J Clin Lab Invest"},{"key":"key20220826100500_b22-ol-24-03-13429","doi-asserted-by":"publisher","first-page":"107296","DOI":"10.1016\/j.intimp.2020.107296","article-title":"Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer","volume":"91","author":"Zhou","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"key20220826100500_b23-ol-24-03-13429","doi-asserted-by":"publisher","first-page":"e0257484","DOI":"10.1371\/journal.pone.0257484","article-title":"Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?","volume":"16","author":"Chmielewska","year":"2021","journal-title":"PLoS One"},{"key":"key20220826100500_b24-ol-24-03-13429","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/CMR.0000000000000739","article-title":"Prognostic impact of thyroid dysfunctions on progression-free survival in patients with metastatic melanoma treated with anti-PD-1 antibodies","volume":"31","author":"Frelau","year":"2021","journal-title":"Melanoma Res"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T07:05:09Z","timestamp":1661497509000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2022.13429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,13]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,7,13]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2022.13429","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,13]]},"article-number":"309"}}